Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2025-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞关于董事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election and nomination of the company's board of directors for the upcoming term. It details the candidates for non-independent and independent directors, their qualifications, and compliance with relevant laws and regulations. The document is issued by the company's board and is dated April 26, 2025. It does not contain financial statements, audit information, or detailed financial results. It is clearly about changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is under 5,000 characters but it is not merely announcing the publication of a report; it is itself the announcement of board changes. Therefore, the correct classification is MANG with high confidence.
2025-04-25 Chinese
神州细胞2024年年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Beijing Sinocelltech Biotech Co., Ltd., including the date, voting methods, agenda items, and instructions for shareholders. It includes information about the election of board members, approval of the 2024 annual report, financial statements, profit distribution, and other corporate governance matters. The document is not the annual report itself but a formal announcement and invitation to the AGM with detailed procedural information and attachments such as proxy forms and voting instructions. The length is over 6000 characters, indicating a comprehensive notice rather than a brief announcement. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-25 Chinese
神州细胞2024年年度报告
Annual Report Classification · 100% confidence The document is titled "北京神州细胞生物技术集团股份公司2024 年年度报告" which translates to "Beijing Sinocelltech Group Co., Ltd. 2024 Annual Report." It contains detailed financial data for the year 2024, including revenue, net profit, quarterly financial data, management discussion and analysis, company governance, risk factors, and audit opinions. The document is lengthy (15,000 characters) and includes comprehensive financial statements and management commentary. It also mentions the audit report by an accounting firm with an unqualified opinion, which is typical for an annual report. The presence of detailed financial metrics, management discussion, and audit information confirms this is the full Annual Report for the fiscal year 2024, not just an announcement or summary. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-04-25 Chinese
神州细胞2024年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report". It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements including balance sheets, profit and loss statements, cash flow statements, and notes. The document is about the fiscal year 2024 ending December 31, 2024. The presence of detailed audit procedures, auditor's opinion, and comprehensive financial data confirms this is a standalone audit report rather than a full annual report or other filing. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the correct classification is Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
神州细胞董事会关于独立董事2024年度独立性自查情况的专项意见
Board/Management Information Classification · 95% confidence The document is a board statement regarding the independence of the company's independent directors for the year 2024. It references regulatory guidelines and confirms the independence of specific directors. This is a governance-related disclosure about board members' status and compliance with independence requirements. It does not contain financial data, audit results, or voting outcomes. Therefore, it fits best under Board/Management Information (MANG), which covers announcements about board or senior management matters.
2025-04-25 Chinese
神州细胞关于参加2024年度科创板创新药行业集体业绩说明会暨召开2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Beijing Sinocell Technology Group Co., Ltd. about participating in a 2024 annual innovation drug industry collective performance explanation meeting and holding the 2025 first quarter performance explanation meeting. It specifies the meeting date, time, location, and participation details. It references that the company has already published the 2024 annual report and 2025 first quarter report on April 26, 2025, and this meeting is to explain and interact with investors regarding those reports. The document is short (1580 characters) and serves as a notice about the upcoming investor presentation event rather than containing the actual financial data or detailed report itself. Therefore, it is best classified as an Investor Presentation (IP) announcement or notice. Given the detailed description of the meeting and interaction with investors, the classification is Investor Presentation (IP).
2025-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.